Clinical Trial Update: UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating UCN-01 in combination with Topotecan for recurrent, persistent, or progressive advanced ovarian epithelial, fallopian tube, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Topotecan (topotecan)
• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED